If you have issues viewing or accessing this file contact us at NCJRS.gov. National institute on Drug Abuse ,/1 f "--1 MONOGRAPH SERIES P @bl® ss De esdesee o o~ ~he •dings.nnua0 Scientific Needing i© ~,mmi~ee on Prob0ems Dependence, Inc. i00760-i007i I~ ~) NationalU.S.Department Institute ofJustice This documenl has been reproduced exactly as received from the person or organization originaling it. Points of vew o opinions s[ated in this documenl are those OI the authors and do not necessarily II represenl lhe official position or policies of the National Institute of Justice. Permission Io reproduce this col=,y,~ malerial has been granled by Public Domain/US Department of Health and Human Services Io Ihe National Criminal Justice Reference $e~ice (NCJR$). Ill DEPARTMENTOF HEALTHkN0 Further reproduction outside of fhe NCJRS system requires permis- le sion Of the ~ owner. q i I I ! I I ! I I .! I i i I I I | problems of~Drug Depe~6ence, 1980 | i Proceedings of the 42nd Annual Scientific Meeting, I The Committee on Problems of Drug Dependence, Inc. J I Editor: Louis S. Harris, Ph.D. II II II NIDA Research Monograph 34 February 1981 II I DEPARTMENTOF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse Division of Research I! 5600 Fishers Lane Rockville, Maryland 20857 II For sale by the Stlperinten(lent of Documents, U.S. Government Printing Office 'tVnshington, I).C, 20402 I II The NIDA Research Monograph series is prepared by the Division of Research of the National Institute on Drug Abuse. Its primary objective is to provide critical reviews of research problem areas and techniques, the content of--- state-of-the-art conferences, integrative research reviews and significant original research. Its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community. Editorial Advisory Board Avram Goldstein, M.D. - - Addiction Research Foundation Polo Alto, Colifornio -~ Jerome Jaffe, M.D. College of Physicions ond Surgeons - Columbia University, New York Reese T. Jones, M.D. Longley Porter Neuropsychiotric Institute University of Colifornio Son Francisco. California William McGIothlin, Ph.D. Depodment of Psychology. UCLA Los Angeles. California Jack Mendelson, M.D. Alcohol ond Drug Abuse Reseorch Center Horvo~d Medical School McLeon Hospital Belmont. Mossochusetts Helen Nowlis, Ph.D. / Office of;Drug Educotion. DHitS Washington, D.C. Lee Robins, Ph.D. Woshington University School of Medicine St. Louis, Missouri NIDA Research Monograph series William Pollin, M.D. DIRECTOR, NIDA Marvin Snyder, Ph.D. DIRECTOR, DIVISION OF RESEARCH, NIDA Robert C. Petersen, Ph.D. EDITOR-IN-CHIEF Eleanor W. Waldrop MANAGING EDITOR Porklawn Building. 5600 Fishers Lone, Rc~kville. Maryland 20857 Iw, I Problems of Drug Dependence, I ~80 i Proceedings of the 42nd Annual Scientific Meeting, The Committee on Problems of Drug Dependence, - ' Inc. ~BERS, C(IX~fITrEE ON PROBLI~4S OF DRUG DEPEND~CE, INC. Dr. Joseph Cochin, Chairman Dr. Joseph Brady I Dr. Troy Duster Dr. Charles Corodetzky Dr. Louis Harris Dr. Theresa Marwood Dr. Arthur Jacobson I Dr. Jerome Jaffe Dr. Arthur Keats Dr. Harold Kalant Dr. Everette May I Dr. Jack Mandelson Dr. C.R. Schuster Dr. Henry Swain I E~CUTIVE SECRETARY Dr. Leo Hollister I M[~ERS t BOARDOF DIRECTORS Dr. E.L. Way, Chairman Am. Soc. Pharmacol. Exptl. ?her. Dr. D.X. Freedman I Am. Psychiatric Assn. Dr. K.F. Killam Am. Coil. Neuropsythopharmacol t Dr. Everette May I Am. Chemical Society Dr. Edward C. Senay Am. Medical Assn. Dr. Beny J. Primm I Nat'l Medical Assn. Dr. James Woods Am. Psychological Assn. Dr. Raymond W. Houde I Am. Soc. Clin. Pharmacol. Ther. I I Mt94BERSt PROGRAM CONI~4ITTEE Dr. Louis S. Harris, Chairman I Dr. Everette L. May Mrs. Rena Holliday MI~IBERS~ C,(3M'4ITI'EEON ARRANGEMENTS I Dr. Joseph Cochin Dr. Louis S. Harris Dr. Jack Mendelson I I I I I I I I I I I I I I m ACKNO~MENT The papers in this monograph were presented or read by title at the 42nd Annual Scientific Meeting of I the Committee on Problems of Drug Dependence, Inc., in Hyarmis, Nassachusetts, on June 16-19, 1980. Opinions expressed in the papers are those of the authors and do not necessarily reflect the opinions or official policy of the National Institute on Drug I Abuse; Alcohol, Drug Abuse, and Mental Health Admin- istration; Public Health Service; or the Department I of Health and Htmmn Services. The National Institute on Drug Abuse has obtained permission from the copyright holder to print ! material, as noted, on page 69. Further repro- doction of this material without specific permission of the copyright holder is prohibited. All other material except quoted passages from copyrighted sources is in the public domain and may be repro- I duced without permission. Citation as to source is appreciated. The United States Government does not endorse or I favor any specific commercial product or commodity. Trade or proprietary names appearing in this publi- cation are used only because they are considered ! essential in the context of the studies reported herein. m Library of Congress catalog card nt~ber 81-600016 ll~ publication nt~nber (AIN) 81-i058 Printed 1981 I NIDA Research .Vonographs are indexed in the Index Medicus. They are selectively included in the coverage of Bioseienees Information Service, Chemical I Abstracts, Current Contents, Psychological Abstracts, and Psychopharmacology Abstracts, m i m m I CONTRIBUTING FIRMS r 1979-80 The following firms have supported the work of the Committee on I Problems of Drug Dependence, Inc., through contributions during the previous fiscal year. I Abbott Laboratories American Hoechs t C.H. Boehringer Sohn Bristol Laboratories I Burroughs Wellcome ~ Company f~emie Linz AG Clin-Midy of America, Inc. Eli Lilly and Company I Endo Laboratories, Inc. Hoffman- LaRoche, Inc. ICI Americas) Inc. l Knoll Pharmaceutical Company Lederle Laboratories McNeil Laboratories Mead-Johnson Merck) Sharpe) and Dohme Merrell-National Laboratories) Inc. I Miles Laboratories) Inc. Ortho Pharsaceut icals Pennwal t Corporation Pfizer Central Research I Reckitt ~ Coleman Products, Ltd. A.H. Robins Company Sando z Ltd. Sando z-Wander p Inc. I G.D. Searle Company SISA) Inc. Smith, Kline ~ French E.R. Squibb ~ Sons, Inc. I Sterling Drug, Inc. The Upjohn Company USV Pharmaceutical Corp. Wyeth Laboratories I I I I vl I I I I I Foreword I In each year's calendar of scientific events related to drug abuse, the Annual Scientific Meeting of the Conmittee on Problems of Drug Dependence, Inc., is an occasion of outstanding importance. I The membership of the CPDD represents a broad spectrum of exper- tise that includes pharmacology, clinical medicine, psychiatry, , public health, chemistry, and the social sciences. The Committee maintains liaison with Coverament regulatory and research agencies, I with the pharmaceutical industry, with national and international asencies that are interested in drug dependence and abuse, and with educational and treatment facilities. I The proceedings of each annual CPDD meeting are a comprehensive gathering of reports on current research in all aspects of drug abuse and drug dependence. Topics presented in Problems of Drug Dependence~ 1980 include the effects of drugs on the central ner- I vous system, their pharmacological action, biological disposition, safety, abuse potential, and clinical usefulness. Annual progress reports of NIDA-supported dependence studies of new compounds are included, in addition to the 40 papers presented and 6 papers read by title at the 42nd Annual Scientific Meeting in Hyannis, Massa- I chusetts, on June 18-20, 1980. There is also an extensive index. Some of the papers have been condensed by the authors to meet space limitations of this volume. I In the belief that readers with widely diverse interests will find this timely review of value, the National Institute on Drug Abuse is pleased, for the second year, to publish in its Research ~ono- graph series the Proceedings of the Annual Scientific Meeting of I the Committee on Problems of Drug Dependence, Inc. William Pollin, M.D. Director I National Institute on Drug Abuse i I I vii I I I l I I I I I I I I I I II II II I I I I, I I I Papers Presented at the 42nd Annual I CPDD Meeting I I I I I I i I I ! I I I I I I I I I I I I i I II II ! Dynorphin I Nathan B. Eddy Memorial Award Lecture I A. Goldstein I It is indeed a very great hGnor to be chosen as recipient of the 1980 Nathan B. Eddy Memorial Award. Dr. Eddy was one of the truly great picneers in the field of opiate research and, in more ways i than one, my own research o~s inspiratice to what he contributed to our field. I have stood here so often before, ce the platform at previous meetings of CPDD, presenting SaTe research finding, while Dr. Eddy -- right there in the second row -- listened and took notes. I can re~emher if cne said anything at all that lacked I sufficient experirmntal evidence or was too speculative, he would look up suddenly, then scribble more vigorously in his notebook. ~nd afterwards, in corridor discussion, cee would have to defend cne's ccnclusices against his &harp and perceptive criticisr~. It has been said that if we accomplish anything at all in science, I it is tecause we can stand Gn the sh(m/lders of giants. Besides Dr. Eddy, there have been other giants in our field -- some of them in , this room today -- ups% whose shoulders I was lucky enough to stand.